A double - blind , placebo - controlled study of fluvoxamine in adults with <font color="blue">autistic_1</font> <font color="blue">disorder_1</font> <font color="blue">._1</font> <font color="blue">
<br>
<br>_1</font> BACKGROUND Autistic disorder is characterized by a fundamental disturbance in social interaction , impairments in communication , and a markedly restricted repertoire of activities and interests . Abnormalities in the serotonin neurotransmitter system have been identified in some persons with autism . No consistently effective and safe drugs have been developed for treating the symptoms of autism . 
<br> METHODS Thirty adults with autistic disorder completed a 12-week double - blind , placebo - controlled trial of the potent and selective serotonin uptake inhibitor fluvoxamine maleate . <font color="blue">Behavioral_2</font> <font color="blue">ratings_2</font> were obtained at baseline and after 4 , 8 , and 12 weeks of treatment . 
<br> RESULTS Eight ( 53% ) of 15 patients in the fluvoxamine - treated group were categorized as responders compared with none of 15 in the placebo group ( P = .001 ) . Fluvoxamine was superior to placebo in <font color="blue">reducing_1</font> <font color="blue">repetitive_6</font> <font color="blue">thoughts_6</font> <font color="blue">and_6</font> <font color="blue">behavior_6</font> ( P < .001 ) , <font color="blue">maladaptive_6</font> <font color="blue">behavior_6</font> ( P < .001 ) , and <font color="blue">aggression_6</font> ( P < .03 ) , and in <font color="blue">improving_1</font> <font color="blue">some_1</font> <font color="blue">aspects_1</font> <font color="blue">of_1</font> <font color="blue">social_6</font> <font color="blue">relatedness_6</font> ( P < .04 ) , especially <font color="blue">language_5</font> <font color="blue">usage_5</font> ( P < .008 ) . Treatment response was not correlated with <font color="blue">age_1</font> <font color="blue">level_1</font> <font color="blue">of_1</font> <font color="blue">autistic_1</font> <font color="blue">behavior_1</font> <font color="blue">,_1</font> or <font color="blue">full_1</font> <font color="blue">-_1</font> <font color="blue">scale_1</font> <font color="blue">IQ_1</font> <font color="blue">._1</font> Other than <font color="blue">mild_5</font> <font color="blue">sedation_5</font> <font color="blue">and_5</font> <font color="blue">nausea_5</font> in a few patients , fluvoxamine was well tolerated . <font color="blue">No_1</font> <font color="blue">dyskinesias_5</font> <font color="blue">,_5</font> <font color="blue">adverse_5</font> <font color="blue">cardiovascular_5</font> <font color="blue">events_5</font> <font color="blue">,_5</font> <font color="blue">or_5</font> <font color="blue">seizures_5</font> <font color="blue">occurred_2</font> <font color="blue">._2</font> 
<br> CONCLUSIONS Fluvoxamine is more <font color="blue">effective_1</font> than placebo in the short - term treatment of the <font color="blue">symptoms_1</font> <font color="blue">of_1</font> <font color="blue">autistic_1</font> <font color="blue">disorder_1</font> in adults . Controlled studies of fluvoxamine and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism .